BBOT - BridgeBio Oncology Therapeutics Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$19.00
DETAILS
HIGH:
$22.00
LOW:
$15.00
MEDIAN:
$20.00
CONSENSUS:
$19.00
UPSIDE:
283.84%
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2022 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | ||||||||||||
| R&D Expenses | 49.2 | 39.8 | 38.1 | 35.1 | 27.4 | 20.6 | 19.5 | 17.9 | 22.5 | 13.2 | 0 | 0 |
| SG&A Expenses | 11.0 | 6.4 | 5.3 | 14.1 | 2.7 | 2.5 | 2.3 | 1.8 | 1.4 | 2.3 | 0.0 | 0.0 |
| Other Expenses | 0 | (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses | 60.2 | 46.0 | 43.4 | 49.2 | 30.1 | 23.1 | 21.9 | 19.7 | 23.9 | 15.4 | 0.0 | 0.0 |
| Operating Income | ||||||||||||
| Operating Income | (60.2) | (46.2) | (43.4) | (49.2) | (30.1) | (23.1) | (21.9) | (19.7) | (23.9) | (15.4) | (0.0) | (0.0) |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Income | 3.6 | 3.9 | 4.4 | 3.4 | 2.1 | 1.8 | 2.1 | 2.5 | 2.4 | 1.2 | 0 | 0 |
| Profitability | ||||||||||||
| EBITDA | (56.5) | (46.0) | (43.2) | (49) | (29.9) | (23.1) | (21.8) | (19.6) | (23.8) | (15.4) | (0.0) | (0.0) |
| EBIT | (56.5) | (46.2) | (43.4) | (49.2) | (30.1) | (23.1) | (21.9) | (19.7) | (23.9) | (15.4) | (0.0) | (0.0) |
| Income Before Tax | (56.5) | (42.1) | (38.8) | (44.8) | (28.4) | (22.1) | (19.7) | (17.3) | (21.8) | (15.4) | (0.0) | (0.0) |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (56.5) | (42.1) | (38.8) | (44.8) | (28.4) | (22.1) | (19.7) | (17.3) | (21.8) | (15.4) | (0.0) | (0.0) |
| Per Share Data | ||||||||||||
| EPS (Basic) | -705.20 | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 | -1075.56 | -0.74 | 0.09 | 0.05 | -0.00 | – |
| EPS (Diluted) | -705.20 | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 | -1075.56 | -0.74 | 0.09 | 0.05 | -0.00 | -0.00 |
| Shares Outstanding | 0.1 | 31.1 | 31.1 | 23.5 | 23.5 | 23.5 | 0.0 | 23.5 | 23.5 | 22.0 | 20.5 | 20.5 |
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Assets | ||||||||||||
| Cash & Cash Equivalents | 54.1 | 52.7 | 373.7 | 408.7 | 31.5 | 26.2 | 1.7 | 1.8 | 1.8 | 1.8 | 0 | 0 |
| Short-Term Investments | 171.6 | 199.6 | 51.8 | 59.5 | 99.9 | 109.5 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0.1 | 0.4 | 0.2 | 1.1 | 0.0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 16.7 | 14.1 | (0.4) | 7.5 | 5.6 | 5.6 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | 242.4 | 266.5 | 425.5 | 476.0 | 142.3 | 141.3 | 1.9 | 2.0 | 2.1 | 2.1 | 0 | 0 |
| Non-Current Assets | ||||||||||||
| Property, Plant & Equipment | 3.0 | 3.2 | 3.3 | 3.3 | 3.4 | 3.4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 136.7 | 0.1 | 0 | 0 | 0 | 192.4 | 190.2 | 187.6 | 185.2 | 0 | 0 |
| Other Non-Current Assets | 131.3 | 11.2 | 18.8 | 5.5 | 5.5 | 5.1 | 0.0 | 0.1 | 0.2 | 0.2 | 0.3 | 0.1 |
| Total Non-Current Assets | 134.3 | 151.1 | 22.9 | 8.8 | 8.9 | 8.5 | 192.5 | 190.3 | 187.8 | 185.4 | 0.3 | 0.1 |
| Total Assets | 376.7 | 417.6 | 448.4 | 484.8 | 151.3 | 149.8 | 194.4 | 192.3 | 189.9 | 187.5 | 0.3 | 0.1 |
| Current Liabilities | ||||||||||||
| Account Payables | 6.7 | 12.1 | 1.4 | 3.6 | 2.2 | 3.7 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-Term Debt | 0.6 | 0.5 | 0.5 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.1 | 0.0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 44.4 | 28.6 | 27.4 | 4.5 | 2.7 | 5.7 | 0 | 0.1 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | 51.6 | 43.3 | 35.0 | 35.7 | 27.3 | 24.1 | 0.2 | 0.1 | 0.1 | 0.0 | 0.4 | 0.2 |
| Non-Current Liabilities | ||||||||||||
| Long-Term Debt | 2.0 | 0 | 2.2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 349.2 | 323.2 | 5.5 | 0 | 0 | 0 | 0 | 0 |
| Total Non-Current Liabilities | 2.0 | 2.1 | 2.2 | 2.4 | 351.7 | 325.8 | 5.5 | 5.5 | 5.5 | 5.5 | 0 | 0 |
| Total Liabilities | 53.6 | 45.4 | 37.3 | 38.1 | 379.0 | 349.9 | 5.7 | 5.6 | 5.6 | 5.5 | 0.4 | 0.2 |
| Stockholders' Equity | ||||||||||||
| Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0 | 0 | 192.4 | 190.2 | 187.6 | 185.2 | 0.0 | 0.0 |
| Retained Earnings | (455.1) | (398.7) | (356.6) | (317.8) | (273.0) | (244.6) | (3.7) | (3.5) | (3.4) | (3.2) | (0.1) | (0.0) |
| Accumulated Other Comprehensive Income | (1.0) | (1.0) | 0.0 | 0.0 | 0.1 | 0.2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Stockholders' Equity | 323.1 | 372.3 | 411.1 | 446.7 | (227.7) | (200.0) | 188.7 | 186.7 | 184.3 | 182.0 | (0.1) | (0.0) |
| Total Liabilities & Equity | 376.7 | 417.6 | 448.4 | 484.8 | 151.3 | 149.8 | 194.4 | 192.3 | 189.9 | 187.5 | 0.3 | 0.1 |
| Debt Metrics | ||||||||||||
| Total Debt | 2.5 | 2.6 | 2.8 | 2.9 | 2.8 | 2.6 | 0 | 0 | 0 | 0 | 0.1 | 0.0 |
| Net Debt | (51.5) | (50.0) | (370.9) | (405.9) | (28.7) | (23.6) | (1.7) | (1.8) | (1.8) | (1.8) | 0.1 | 0.0 |
| Metric | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||
| Net Income | (56.5) | (42.1) | (38.8) | (44.8) | (28.4) | (0.5) | 2.0 | (17.3) | 2.2 | (15.4) | (0.0) |
| Depreciation & Amortization | 0.1 | 0.2 | 0.2 | 0.4 | 0.2 | 0 | 0 | 0.2 | 0 | 0.1 | 0 |
| Stock-Based Compensation | 7.2 | 0 | 2.9 | 0 | 0.9 | 0.1 | 0.1 | 0 | 0.1 | 1.6 | 0 |
| Change in Working Capital | 9.6 | 2.2 | (6.5) | 10.4 | 4.5 | 0.0 | 0.1 | 11.5 | 0.1 | 5.0 | 0 |
| Other Non-Cash Items | (4.8) | 3.8 | (0.1) | (36.7) | (0.4) | (0.3) | (2.2) | (33.7) | (2.4) | 0 | 0.0 |
| Operating Cash Flow | (44.4) | (35.9) | (42.2) | (70.6) | (23.3) | (0.7) | (0.1) | (39.3) | (0.0) | (8.9) | 0 |
| Investing Activities | |||||||||||
| Capital Expenditure | (0.0) | (0.0) | (0.1) | (0.5) | (0.2) | 0 | 0 | (0.0) | 0 | (0.0) | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (7.5) | (311.6) | (21.0) | (62.9) | (34.0) | 0 | 0 | 29.6 | 0 | 0 | 0 |
| Sales/Maturities of Investments | 53.3 | 26.3 | 28.9 | 129.0 | 43.9 | 0 | 0 | 6.0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.4 | 0 | 2.4 | 0 |
| Investing Cash Flow | 45.7 | (285.4) | 7.8 | 65.6 | 9.6 | 0 | 0 | 37.9 | 0 | 2.4 | 0 |
| Financing Activities | |||||||||||
| Net Debt Issuance | 0 | 0 | 0 | 373.5 | 0 | 0 | 0.2 | 0.2 | 0 | 0 | 0 |
| Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | (0.1) | (0.6) | (11.7) | (3.3) | 0 | 187.0 | 1.1 | 0 | 0 | 0 |
| Financing Cash Flow | 0.0 | 0.3 | (0.6) | 384.0 | 19.0 | 0 | 0 | 19.8 | 0 | 6.6 | 0 |
| Cash Position | |||||||||||
| Net Change in Cash | 1.4 | (321.0) | (35.1) | 408.1 | 5.3 | (0.7) | (0.1) | (0.0) | (0.0) | 0.2 | 0 |
| Cash at Beginning | 52.8 | 373.7 | 408.9 | 0.7 | 26.3 | 1.7 | 1.8 | 1.8 | 1.8 | 0.2 | 0 |
| Cash at End | 54.2 | 52.7 | 373.8 | 408.7 | 31.6 | 1.0 | 1.7 | 1.8 | 1.8 | 0.4 | 0 |
| Free Cash Flow | (44.4) | (35.9) | (42.3) | (71.2) | (23.5) | (0.7) | (0.1) | (39.4) | (0.0) | (8.9) | 0 |
| Key Metrics | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2022 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | (0.2) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | (60.2) | (46.2) | (43.4) | (49.2) | (30.1) | (23.1) | (21.9) | (19.7) | (23.9) | (15.4) | (0.0) | (0.0) |
| Net Income | (56.5) | (42.1) | (38.8) | (44.8) | (28.4) | (22.1) | (19.7) | (17.3) | (21.8) | (15.4) | (0.0) | (0.0) |
| EPS (Diluted) | -705.20 | -1.35 | -1.25 | -1.90 | -1.21 | -0.94 | -1075.56 | -0.74 | 0.09 | 0.05 | -0.00 | -0.00 |
| Balance Sheet | ||||||||||||
| Cash & Equivalents | 54.1 | 52.7 | 373.7 | 408.7 | 31.5 | 26.2 | 1.7 | 1.8 | 1.8 | 1.8 | 0 | 0 |
| Total Assets | 376.7 | 417.6 | 448.4 | 484.8 | 151.3 | 149.8 | 194.4 | 192.3 | 189.9 | 187.5 | 0.3 | 0.1 |
| Total Debt | 2.5 | 2.6 | 2.8 | 2.9 | 2.8 | 2.6 | 0 | 0 | 0 | 0 | 0.1 | 0.0 |
| Stockholders' Equity | 323.1 | 372.3 | 411.1 | 446.7 | (227.7) | (200.0) | 188.7 | 186.7 | 184.3 | 182.0 | (0.1) | (0.0) |
| Cash Flow | ||||||||||||
| Operating Cash Flow | (44.4) | (35.9) | (42.2) | (70.6) | (23.3) | (0.7) | (0.1) | (39.3) | (0.0) | (8.9) | 0 | |
| Capital Expenditure | (0.0) | (0.0) | (0.1) | (0.5) | (0.2) | 0 | 0 | (0.0) | 0 | (0.0) | 0 | |
| Free Cash Flow | (44.4) | (35.9) | (42.3) | (71.2) | (23.5) | (0.7) | (0.1) | (39.4) | (0.0) | (8.9) | 0 | |